Intas Pharmaceuticals’ new warning letter from the U.S. FDA reads like a checklist of what not to do when the regulator pays a visit to your manufacturing facility. The FDA handed Intas a five ...

Coherus has agreed to sell its biosimilar Udenyca—which references Amgen’s febrile neutropenia drug Neulasta—to Intas Pharmaceuticals for up to $558.4 million. The deal, which is expected to ...

Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are in short supply, was seen pouring acetic acid in a trash bin containing documents at a ...

Drug-maker Intas Pharmaceuticals has merged all its group companies and subsidiaries over concerns about low profits. Along with the mergers, the company has also worked out a plan of succession ...

The agency cited Intas Pharmaceuticals for several violations of so-called good manufacturing practices, including problems with data integrity, standard documentation practices, accuracy ...

Ahmedabad: Intas Pharmaceuticals Ltd has announced a strategic exclusive licensing agreement with mAbxience (a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma ...

Intas Pharmaceuticals Limited has informed that its manufacturing facility SEZ (Pharmez) near Ahmedabad has been listed under ‘Import Alert’ by the US Food and Drug Administration (USFDA).

A Triangle pharmaceutical firm is expanding its portfolio as its parent company completes a $500 million deal. © 2025 American City Business Journals. All rights ...